InvestorsHub on MSN
BioAffinity Technologies posts 2025 results as CyPath lung testing growth accelerates
Affinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a ...
The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...
Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results